Fredag 25 April | 17:28:09 Europe / Stockholm

Prenumeration

2025-04-25 09:46:00

Q1 is spot on expectations in most aspects. The organic CER growth of 14% is expected to improve with higher delivery capacity and solid demand for the core business. Later in 2025 and over the next three years, XVIVO is also in a good position to benefit from increasing launch support. XVIVO continues to invest in sustainable growth, including a higher inventory level and commercial capacity, in 2025, ahead of substantial launch support.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/